Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

A dietetics professor explains who should and should not embrace the latest weight-loss drugs. Holiday weight gain hits home ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

When drugmakers pulled the weight-loss drug fen-phen off the market in 1997, my mom was devastated. Not because the FDA ...